Patient Reported Outcomes while Manipulating the Immune System in autoimmune Encephalitis

• Conditions: autoimmune encephalitis; autoimmune inflammation of the brain; 10007951

• Registration Number: NL-OMON50854
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

1. Adults or adolescents from the age of 16 years;
2. Sufficiently fluent in Dutch;
3. Have a clinical high suspicion of an autoimmune encephalitis or a
paraneoplastic neurological syndrome
4. Antibodies are detected in serum and/or CSF with cell-based assay and
affirmed with immunohistochemistry

Exclusion Criteria

1. Impossible to assess outcome related to autoimmune encephalitis due to
pre-existing comorbidities, objectified as a premorbid mRS over two.
2. The patient and/or legal representative is withholding informed consent;
3. The patient withdraws, after initial consent.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The outcome of patients with an autoimmune encephalitis over time, also per<br /><br>subtype of autoimmune encephalitis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Disease-specific valid patient-reported outcome measure(s), with discriminatory<br />value in the acute as well as the chronic phase of the disease.</p>